BELANOFF JOSEPH K 4
4 · CORCEPT THERAPEUTICS INC · Filed Mar 27, 2026
Research Summary
AI-generated summary of this filing
Corcept Therapeutics (CORT) CEO Joseph Belanoff Sells 26,198 Shares
What Happened Joseph K. Belanoff, CEO of Corcept Therapeutics (CORT), sold 26,198 shares on March 25, 2026 in an open-market transaction. The weighted average sale price was $50.07 per share (range $50.00–$50.32), for total proceeds of approximately $1,311,826. The Form 4 reports this as a sale (transaction code S).
Key Details
- Transaction date: 2026-03-25 (reported on Form 4 filed 2026-03-27).
- Price: weighted average $50.07; actual sale prices ranged $50.00–$50.32 (see footnote F2).
- Shares sold: 26,198; Proceeds ≈ $1,311,826.
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Footnotes: transaction executed pursuant to a Rule 10b5-1 trading plan adopted 11/26/2024 (F1); weighted-average and price range note (F2); Belanoff disclaims beneficial ownership of certain trust-held shares except for pecuniary interest (F3). Power of attorney used to sign the form is on file with the SEC.
- Timeliness: Filed within the required Form 4 window (reported two days after the trade).
Context This was a planned sale under a 10b5-1 trading plan, which typically indicates the transactions were pre-scheduled and not an ad hoc sale based on current company knowledge. Sales under 10b5-1 plans are common and are generally viewed as routine rather than a direct signal of executive sentiment. No options were exercised and no awards or gifts are reported in this filing.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-03-25$50.07/sh−26,198$1,311,826→ 2,918,326 total(indirect: By Trust)
Footnotes (3)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
- [F2]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.32 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F3]Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.